The therapeutic potential of monoamine oxidase inhibitors

By M. Youdim, D. Edmondson, K. Tipton. Nature Reviews Neuroscience, 2006

1,300 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

13 reasons why the brain is susceptible to oxidative stress (2018, background): “line, MOA-A preferentially metabolises 5-hydroxytryptamine whereas MOA-B prefers 2-phenylethylamine [124,125].”
The Role of Oxidative Stress in Parkinson’s Disease (2013, background): “However, with neuronal degeneration that occurs in PD and aging, MAO-B located in glial cells increases and becomes the predominant enzyme to metabolize dopamine [50–52], which is taken up by astrocytes via sodium-dependent and independent mechanisms [53–55].”
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain (2017, background): “Because clinical depression is associated with a decreased system of NE and/or 5-HT content in some regions of the CNS, the antidepressant effect of the classical monoamine oxidase inhibitor (MAOI) might be related to its ability to increase the NE and/or 5-HT levels of these sites [21, 85].”
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. (2015, neutral): “, 2002), possibly because dopamine can be broken down into inactive metabolites by a set of enzymes, such as monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT) (Youdim et al., 2006).”